Each issue of Pharmaceutical Engineering® covers a wide range of topics relevant to the pharmaceutical industry, including scientific, technological, and regulatory advancements throughout the entire...
ISPE’s official blog, iSpeak accepts contributions from our Members and professionals in the pharma industry.
Each issue of Pharmaceutical Engineering® covers a wide range of topics relevant to the pharmaceutical industry, including scientific, technological, and regulatory advancements throughout the entire...
On the closing morning of the 2025 ISPE Europe Annual Conference, Jackson presented MHRA’s Policy for the Future and Globalized Industry.
At the 2025 ISPE Europe Annual Conference held 12-14 May 2025 in London, the European Medicines Agency (EMA)’s Head of Quality and Safety of Medicines Department, Evdokia Korakianiti, highlighted the many...
In a world defined by rapid scientific progress and evolving market demands, the ability to adapt, innovate, and sustain excellence is no longer optional—it’s essential. The 2025 ISPE Biotechnology Conference,...
Each issue of Pharmaceutical Engineering® covers a wide range of topics relevant to the pharmaceutical industry, including scientific, technological, and regulatory advancements throughout the entire...
At the 2024 ISPE Annual Meeting & Expo, a session titled “Regulatory Surveillance and Advocacy” was presented by Christine Moore, PhD, Executive Director, Quality Systems and Compliance at Organon LLC. Moore spoke about the definition of regulatory surveillance of policy and standards, and going beyond surveillance into regulatory intelligence, specifically related to inspections and...
Pharma 4.0™ represents a transformative shift within the pharmaceutical industry, redefining how medicines are developed, manufactured, and delivered. At its core, Pharma 4.0 involves the integration of advanced digital technologies...
Biomanufacturing is advancing rapidly, and as the industry evolves, so too must the facilities that support it. Therapeutic modalities are becoming more diverse, and with the increasing demand for speed, flexibility, and sustainability in production, biopharmaceutical facilities must be prepared to meet these new challenges.